

Resource Summary Report

Generated by PRECISE-TBI on Sep 8, 2026

Drug Discovery Core Facility

RRID:SCR_022542

Type: Tool

Proper Citation

Drug Discovery Core Facility (RRID:SCR_022542)

Resource Information

URL: <https://www.themiamiproject.org/research-resources/core-facilities/drug-discovery-core/>

Proper Citation: Drug Discovery Core Facility (RRID:SCR_022542)

Description: Core at Miami Project to Cure Paralysis leverages PerkinElmer Opera Phenix Plus high content screening system to provide assay development and phenotypic screening. Facility is also equipped with PerkinElmer Janus G3 liquid handler, featuring modular and variable dispense heads, to automate screening workflows and enhance throughput. Core supports phenotypic and target-based assays. Phenotypic assays range from 2D to 3D, widefield to confocal, and antibody to dye based. It collaborates with users to develop customized assays and analytical pipelines tailored to their specific needs. Current specializations include neurite tracing, lipid droplet quantification, cell viability, morphological and kinetic analyses, phagocytosis, cell marker detection, cell adhesion, among others.

Abbreviations: DDC

Synonyms: Miami Project To Cure Paralysis Drug Discovery Core, Drug Discovery Core

Resource Type: access service resource, core facility, service resource

Keywords: USEDit, ABRF, high content screening, liquid handling, biochemical assays, target engagement assays, phenotypic screening, drug discovery

Resource Name: Drug Discovery Core Facility

Resource ID: SCR_022542

Alternate IDs: ABRF_592

Alternate URLs: <https://coremarketplace.org/?FacilityID=592&citation=1>

Record Creation Time: 20220708T050150+0000

Ratings and Alerts

No rating or validation information has been found for Drug Discovery Core Facility.

No alerts have been found for Drug Discovery Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Capener JL, et al. (2026) Development of NanoBRET cellular target engagement assays in primary neurons for activating mutants of p21-activated kinase 1. bioRxiv : the preprint server for biology.

Njeim R, et al. (2025) Novel Lipophagy Inducers as Potential Therapeutics for Lipid Metabolism Disorders. ACS chemical biology, 20(6), 1406.